title: Increased survival, limb preservation, and prognostic factors for osteosarcoma.
abstract: Preoperative intraarterial (IA) cisplatin (CDP) was administered to 92 patients with nonmetastatic osteosarcoma. The ages of the patients ranged from 4 to 28 years. Sixty-four patients (70%) received 2 or 3 preoperative courses and 28 (30%) received 4 or more. Sixty-two specimens were available for pathologic examination to assess the degree of tumor necrosis. More than 90% tumor destruction was observed in 16 of 42 patients (38%) who received 1 to 3 preoperative courses as opposed to 17 of 20 (85%) who received 4 or more courses. Patients who received 4 or more courses had a 2-fold probability of achieving more than 90% tumor necrosis, and 68% underwent conservative surgery. Of those who received 3 or less courses, 23% underwent conservative surgery. Postoperatively, patients were treated with intravenous (IV) CDP alternating with doxorubicin (ADR) (Adriamycin, Adria Laboratories, Columbus, OH). Pulmonary metastases developed in 36 patients, bone metastases in 2, and local recurrence in 6. Two patients died of cardiac failure without evidence of disease. Thus, 46 patients (50%) were continuously free of disease 18 to 78 months after diagnosis. Univariate and multivariate analyses showed that male sex, low grade preoperative chemotherapy-induced necrosis, and nonosteoblastic histologic condition were prognostic factors predictive of recurrence, while male sex and large tumor size were prognostic factors predictive of death. These results are comparable with those reported by other centers and are superior to our previous experiences that yielded survival rates of 5% to 10%. A substantial number of patients also had the opportunity to achieve tumor removal with conservative surgery.
authors.affiliation: Department of Pediatrics, A. C. Camargo Hospital, Sao Paulo, Brazil.
authors.forename: A S
authors.initials: AS
authors.lastname: Petrilli
authors.forename: F C
authors.initials: FC
authors.lastname: Gentil
authors.forename: S
authors.initials: S
authors.lastname: Epelman
authors.forename: L F
authors.initials: LF
authors.lastname: Lopes
authors.forename: A
authors.initials: A
authors.lastname: Bianchi
authors.forename: A
authors.initials: A
authors.lastname: Lopes
authors.forename: M T
authors.initials: MT
authors.lastname: Figueiredo
authors.forename: E
authors.initials: E
authors.lastname: Marques
authors.forename: N
authors.initials: N
authors.lastname: De Bellis
authors.forename: E
authors.initials: E
authors.lastname: Consentino
mesh_terms: D000293:Adolescent; D000328:Adult; D000671:Amputation, Surgical; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality* / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005121:Extremities / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D009336:Necrosis; D012516:Osteosarcoma / Q000401:mortality* / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin